PartnershipJul 21, 2026, 07:02 AM
Tempest Partners with Senlang for TPST-4003 CAR-T Trial
AI Summary
Tempest Therapeutics announced a strategic partnership with Hebei Senlang Biotechnology to develop its proprietary TPST-4003 product candidate. TPST-4003 is a next-generation in vivo CAR-T candidate designed for autoimmune and oncology indications. Senlang will conduct an investigator-initiated trial in China, enrolling approximately 10 patients with myasthenia gravis or multiple sclerosis, with first patient dosing expected in the fourth quarter of 2026. The agreement also grants Senlang an exclusive option to negotiate a definitive license agreement for TPST-4003 in China.
Key Highlights
- Tempest Therapeutics partnered with Hebei Senlang Biotechnology for TPST-4003.
- TPST-4003 is a next-generation in vivo CAR-T candidate for autoimmune and oncology.
- Senlang will conduct an investigator-initiated trial (IIT) in China.
- The trial will enroll approximately 10 patients with myasthenia gravis or multiple sclerosis.
- First patient dosing is expected in the fourth quarter of 2026.
- Initial safety and pharmacodynamic data are anticipated in the first half of 2027.
- Senlang receives an exclusive option for a definitive license agreement for TPST-4003 in China.
Price Impact
More from TPST